Gene therapy trial aims to halt vision loss in rare inherited eye disease
NCT ID NCT05926583
Summary
This study is testing a gene therapy called AAV5-hRKp.RPGR to see if it is safe and can help preserve or improve vision in Japanese patients with a specific, inherited form of retinitis pigmentosa (XLRP). The therapy involves a one-time injection into the back of both eyes to deliver a working copy of a faulty gene (RPGR) that causes the disease. The main goal is to check for side effects, while also measuring changes in vision over 52 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Hospital Organization Tokyo Medical Center
RECRUITINGMeguro-ku, 1528902, Japan
Conditions
Explore the condition pages connected to this study.